HomeC43 • ETR
add
Cosmo Pharmaceuticals NV
Previous close
€81.00
Year range
€35.60 - €85.50
Market cap
1.36B CHF
Avg Volume
57.00
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 68.12M | 212.03% |
Operating expense | 13.07M | 47.92% |
Net income | 38.00M | 5,013.80% |
Net profit margin | 55.78 | 1,540.59% |
Earnings per share | — | — |
EBITDA | 47.12M | 571.55% |
Effective tax rate | 14.30% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 133.41M | -39.92% |
Total assets | 638.25M | -13.38% |
Total liabilities | 132.87M | -55.51% |
Total equity | 505.39M | — |
Shares outstanding | 16.05M | — |
Price to book | 2.61 | — |
Return on assets | 17.03% | — |
Return on capital | 21.44% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 38.00M | 5,013.80% |
Cash from operations | 49.59M | 540.61% |
Cash from investing | -44.75M | -62.00% |
Cash from financing | -2.68M | 80.12% |
Net change in cash | 2.14M | 106.38% |
Free cash flow | 25.44M | 2,127.23% |
About
Founded
1997
Website
Employees
339
